nsclc news - Search News

FDA, NSCLC and Tagrisso

AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

Zacks.com on MSN · 2d

AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of unresectable,

The American Journal of Manage… · 2d

FDA Approves Osimertinib in Stage III NSCLC

The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.

Monthly Prescribing Reference · 2d

Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.

Cure Today · 3d

FDA Approves Tagrisso for Some With Advanced NSCLC

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.

Seeking Alpha on MSN · 2d

AstraZeneca gets FDA expanded approval for Tagrisso

AstraZeneca (NASDAQ:AZN) has received FDA approval for its drug Tagrisso for the treatment of patients with unresectable Stage 3 EGFR-mutant non-small cell lung cancer, or NSCLC. The agency approved Tagrisso,

Medscape1d

FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

Targeted Oncology1d

Olomorasib Combo Elicits Favorable Efficacy in NSCLC

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

The American Journal of Managed Care1d

Amivantamab Accolades Add Up for NSCLC

On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...

Medscape2d

Minimal Risks With SBRT in Stage I NSCLC

Patients with stage I NSCLC who receive stereotactic body radiotherapy rarely experience acute toxicities or 90-day mortality ...

BioSpace10d

Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Targeted Oncology4d

Building on the Success of Osimertinib in EGFR-Mutated NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...

10d

How Is Non-Small Cell Lung Cancer (NSCLC) Treated?

Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics